Trial Profile
Combined Phase I/II Clinical Study of EMD531444(L-BLP25 or BLP25 Liposome Vaccine) in Subjects With Stage III Unresectable Non-small Cell Lung Cancer Following Primary Chemoradiotherapy.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Dec 2018
Price :
$35
*
At a glance
- Drugs Tecemotide (Primary) ; Cyclophosphamide
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Merck KGaA
- 23 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 15 May 2015 According to a Merck and Co. media release, data from this study will be presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) 2015.